| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.7 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | -0.06 | 0.7 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.7 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.7 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.018 | 0.7 |